Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00513
|
|||||
| Drug Name |
Sulfinpyrazone
|
|||||
| Synonyms |
(+/-)-SULFINPYRAZONE; 1,2-Diphenyl-3,5-dioxo-4-(2'-phenyl-sulfinyl-aethyl)-pyrazolidin; 1,2-Diphenyl-3,5-dioxo-4-(2'-phenyl-sulfinyl-aethyl)-pyrazolidin [German]; 1,2-Diphenyl-3,5-dioxo-4-(2-phenylsulfinylethyl) pyrazolidine; 1,2-Diphenyl-3,5-dioxo-4-(2-phenylsulfinylethyl)pyrazolidine; 1,2-Diphenyl-4-(2'-phenylsulfinethyl)-3,5-pyrazolidinedione; 1,2-Diphenyl-4-(2-(phenylsulfinyl)ethyl)-3,5-pyrazolidinedione; 1,2-Diphenyl-4-(phenylsulfinylethyl)-3,5-pyrazolidinedione; 1,2-Diphenyl-4-[2-(phenylsulfinyl)ethyl-3,5-pyrazolidinedione; 1,2-diphenyl-4-[2-(phenylsulfinyl)ethyl]pyrazolidine-3,5-dione; 4-(2-Benzenesulfinylethyl)-1,2-diphenylpyrazolidine-3,5-dione; 4-(Phenylsulfoxyethyl)-1,2-diphenyl-3,5-pyrazolidinedione; 4-[2-(benzenesulfinyl)ethyl]-1,2-diphenylpyrazolidine-3,5-dione; Anturan; Anturane; Anturane (TN); Anturanil; Anturano; Anturen; Anturidin; Apo Sulfinpyrazone; Apo-Sulfinpyrazone; Apotex Brand of Sulfinpyrazone; Diphenylpyrazone; Enturan; Enturen; G 28,315; G 28315; Novartis Brand of Sulfinpyrazone; Novopyrazone; Nu Pharm Brand of Sulfinpyrazone; Nu Sulfinpyrazone; Nu-Pharm Brand of Sulfinpyrazone; Nu-Sulfinpyrazone; Sulfinpirazona; Sulfinpirazona [INN-Spanish]; Sulfinpyrazine; Sulfinpyrazon; Sulfinpyrazone (JP15/USP/INN); Sulfinpyrazone (SPZ); Sulfinpyrazone [USAN:INN:JAN]; Sulfinpyrazonum; Sulfinpyrazonum [INN-Latin]; Sulfoxyphenylpyrazolidin; Sulfoxyphenylpyrazolidine; Sulphinpyrazone; USAF GE-13
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Arthritis [ICD11:FA5Z] | Approved | [1] | |||
| Gout [ICD11:FA25] | Approved | [1] | ||||
| Therapeutic Class |
Uricosuric Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C23H20N2O3S
|
|||||
| Canonical SMILES |
C1=CC=C(C=C1)N2C(=O)C(C(=O)N2C3=CC=CC=C3)CCS(=O)C4=CC=CC=C4
|
|||||
| InChI |
InChI=1S/C23H20N2O3S/c26-22-21(16-17-29(28)20-14-8-3-9-15-20)23(27)25(19-12-6-2-7-13-19)24(22)18-10-4-1-5-11-18/h1-15,21H,16-17H2
|
|||||
| InChIKey |
MBGGBVCUIVRRBF-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 57-96-5
|
|||||
| Pharmaceutical Properties | Molecular Weight | 404.5 | Topological Polar Surface Area | 76.9 | ||
| Heavy Atom Count | 29 | Rotatable Bond Count | 6 | |||
| Hydrogen Bond Donor Count | 0 | Hydrogen Bond Acceptor Count | 4 | |||
| XLogP |
2.3
|
|||||
| PubChem CID | ||||||
| PubChem SID |
10321460
,11112139
,11335265
,11360504
,11363916
,11366478
,11369040
,11371640
,11374587
,11377202
,11461476
,11466318
,11467438
,11485183
,11486155
,11489140
,11490406
,11492660
,11494836
,117338
,14718483
,14879380
,24899841
,26611933
,26680609
,26747070
,26747071
,29224394
,46500625
,46504918
,47216628
,47290983
,47290984
,47440092
,47588838
,48110300
,48334323
,48416577
,49698736
,50029653
,50100985
,50661502
,53789714
,5632696
,611476
,7847515
,8149541
,8153281
,855982
,9525
|
|||||
| ChEBI ID |
ChEBI:9342
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | MRP2 | Transporter Info | Multidrug resistance-associated protein 2 | Substrate | [2] | |
| References | ||||||
| 1 | Sulfinpyrazone was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export. Br J Cancer. 2000 Aug;83(3):375-83. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.